Neil Clark of Destiny Pharma: SPOR-COV® research reveals very exciting data and sets up potential royalty payments
Episode 1380, May 02, 2023, 08:34 AM
Neil Clark, CEO of Destiny Pharma #DEST describes how SPOR-COV® showed positive results from testing in several COVID-19 and influenza research models, which support potential as prophylactic nasal spray. Also a Phase 1 clinical studies has been completed successfully in Vietnam by HURO and a retail product has been launched there meaning Destiny could be due future royalty payments.
Highlights of the data from these studies show:
1. Prophylaxis of COVID-19 observed in SARS‑CoV‑2 preclinical challenge models.
2. Significant reduction in signs and symptoms of influenza across multiple preclinical models, including a gold-standard model of influenza infection in "Vaccines" journal (James et al., 2022). Studies were conducted across several investigative sites.
3. SPOR-COV nasal spray use as a potential adjunct/booster to existing vaccines is supported by preliminary immunological research.
4. Technical development programme lead by HURO has been successful and enabled a scalable manufacturing process for GMP material.
5. GLP preclinical safety studies successfully completed and therapeutic window supportive of clinical development defined.
About SPOR-COV
SPOR‑COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. Importantly, this product is completely sterile and poses no risk of administering live bacteria. SPOR-COV is different to traditional vaccines in that it utilises the innate immune system with the aim of developing COVID-19 and influenza protection alone or possibly in combination with vaccine therapies a few days after dosing. As an "easy to use" product, for COVID-19 and influenza it has the potential to significantly reduce both infection rates and transmission. The final SPOR-COV product is planned to be straightforward to produce at high volumes and at low cost. Additional attributes are that (i) it can be stockpiled almost indefinitely without the need for cold chain logistics as it is a particularly stable product, (ii) made available globally as a cost-effective measure in the fight against COVID-19 as well as new COVID variants, and (iii) potential efficacy against other respiratory viral infections."
To read the full RNS click here
Highlights of the data from these studies show:
1. Prophylaxis of COVID-19 observed in SARS‑CoV‑2 preclinical challenge models.
2. Significant reduction in signs and symptoms of influenza across multiple preclinical models, including a gold-standard model of influenza infection in "Vaccines" journal (James et al., 2022). Studies were conducted across several investigative sites.
3. SPOR-COV nasal spray use as a potential adjunct/booster to existing vaccines is supported by preliminary immunological research.
4. Technical development programme lead by HURO has been successful and enabled a scalable manufacturing process for GMP material.
5. GLP preclinical safety studies successfully completed and therapeutic window supportive of clinical development defined.
About SPOR-COV
SPOR‑COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. Importantly, this product is completely sterile and poses no risk of administering live bacteria. SPOR-COV is different to traditional vaccines in that it utilises the innate immune system with the aim of developing COVID-19 and influenza protection alone or possibly in combination with vaccine therapies a few days after dosing. As an "easy to use" product, for COVID-19 and influenza it has the potential to significantly reduce both infection rates and transmission. The final SPOR-COV product is planned to be straightforward to produce at high volumes and at low cost. Additional attributes are that (i) it can be stockpiled almost indefinitely without the need for cold chain logistics as it is a particularly stable product, (ii) made available globally as a cost-effective measure in the fight against COVID-19 as well as new COVID variants, and (iii) potential efficacy against other respiratory viral infections."
To read the full RNS click here